BridgeBio Short Long Term Debt vs Current Deferred Revenue Analysis

BBIO Stock

USD 27.77 1.28 4.83%

BridgeBio Pharma financial indicator trend analysis is way more than just evaluating BridgeBio Pharma prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether BridgeBio Pharma is a good investment. Please check the relationship between BridgeBio Pharma Short Long Term Debt and its Current Deferred Revenue accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BridgeBio Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in BridgeBio Stock, please use our How to Invest in BridgeBio Pharma guide.

Short Long Term Debt vs Current Deferred Revenue

Short Long Term Debt vs Current Deferred Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of BridgeBio Pharma Short Long Term Debt account and Current Deferred Revenue. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between BridgeBio Pharma's Short Long Term Debt and Current Deferred Revenue is 0.49. Overlapping area represents the amount of variation of Short Long Term Debt that can explain the historical movement of Current Deferred Revenue in the same time period over historical financial statements of BridgeBio Pharma, assuming nothing else is changed. The correlation between historical values of BridgeBio Pharma's Short Long Term Debt and Current Deferred Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Short Long Term Debt of BridgeBio Pharma are associated (or correlated) with its Current Deferred Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Current Deferred Revenue has no effect on the direction of Short Long Term Debt i.e., BridgeBio Pharma's Short Long Term Debt and Current Deferred Revenue go up and down completely randomly.

Correlation Coefficient

0.49

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Short Long Term Debt

The total of a company's short-term and long-term borrowings.

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Most indicators from BridgeBio Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into BridgeBio Pharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BridgeBio Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in BridgeBio Stock, please use our How to Invest in BridgeBio Pharma guide.At this time, BridgeBio Pharma's Issuance Of Capital Stock is very stable compared to the past year. As of the 25th of December 2024, Enterprise Value is likely to grow to about 8.3 B, while Selling General Administrative is likely to drop about 123 M.

	2021	2022	2023	2024 (projected)
Reconciled Depreciation	5.8M	6.8M	6.5M	4.2M
Total Operating Expenses	646.3M	546.1M	614.2M	443.3M

Reconciled Depreciation Total Operating Expenses

BridgeBio Pharma fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets	Non Current Liabilities Other	Net Working Capital
Total Assets		0.82	0.88	-0.52	0.65	-0.49	0.89	0.67	-0.72	0.9	0.92	0.9	0.8	0.54	0.99	-0.71	0.78	0.76	0.79	0.79	0.77	0.94	0.89	1.0	0.87	0.99
Other Current Liab	0.82		0.97	-0.82	0.87	-0.82	0.91	0.9	-0.89	0.74	0.73	0.9	0.97	0.74	0.75	-0.73	0.96	0.95	0.83	0.79	0.95	0.82	0.91	0.78	0.87	0.72
Total Current Liabilities	0.88	0.97		-0.78	0.87	-0.76	0.88	0.87	-0.91	0.83	0.83	0.9	0.91	0.79	0.84	-0.79	0.97	0.93	0.86	0.89	0.94	0.88	0.88	0.86	0.84	0.81
Total Stockholder Equity	-0.52	-0.82	-0.78		-0.96	0.97	-0.58	-0.95	0.91	-0.59	-0.53	-0.71	-0.75	-0.9	-0.43	0.51	-0.87	-0.9	-0.54	-0.53	-0.9	-0.49	-0.58	-0.47	-0.59	-0.4
Other Liab	0.65	0.87	0.87	-0.96		-0.95	0.69	0.98	-0.98	0.63	0.61	0.77	0.8	0.94	0.58	-0.73	0.94	0.89	0.68	0.71	0.9	0.67	0.69	0.61	0.68	0.54
Net Tangible Assets	-0.49	-0.82	-0.76	0.97	-0.95		-0.61	-0.97	0.88	-0.47	-0.42	-0.73	-0.77	-0.86	-0.39	0.62	-0.87	-0.89	-0.56	-0.52	-0.88	-0.54	-0.61	-0.43	-0.65	-0.35
Property Plant And Equipment Net	0.89	0.91	0.88	-0.58	0.69	-0.61		0.75	-0.71	0.7	0.71	0.92	0.95	0.51	0.85	-0.76	0.8	0.78	0.85	0.73	0.79	0.91	1.0	0.87	0.97	0.84
Net Debt	0.67	0.9	0.87	-0.95	0.98	-0.97	0.75		-0.94	0.61	0.58	0.84	0.85	0.88	0.58	-0.73	0.94	0.93	0.67	0.66	0.93	0.71	0.75	0.62	0.76	0.55
Retained Earnings	-0.72	-0.89	-0.91	0.91	-0.98	0.88	-0.71	-0.94		-0.72	-0.72	-0.76	-0.8	-0.96	-0.66	0.76	-0.96	-0.89	-0.76	-0.81	-0.89	-0.72	-0.71	-0.69	-0.67	-0.62
Accounts Payable	0.9	0.74	0.83	-0.59	0.63	-0.47	0.7	0.61	-0.72		0.99	0.77	0.67	0.62	0.9	-0.46	0.73	0.76	0.69	0.71	0.77	0.72	0.7	0.9	0.67	0.89
Cash	0.92	0.73	0.83	-0.53	0.61	-0.42	0.71	0.58	-0.72	0.99		0.74	0.65	0.61	0.93	-0.52	0.73	0.72	0.73	0.77	0.73	0.76	0.71	0.93	0.66	0.92
Non Current Assets Total	0.9	0.9	0.9	-0.71	0.77	-0.73	0.92	0.84	-0.76	0.77	0.74		0.91	0.59	0.84	-0.71	0.86	0.9	0.74	0.66	0.9	0.9	0.92	0.86	0.96	0.83
Non Currrent Assets Other	0.8	0.97	0.91	-0.75	0.8	-0.77	0.95	0.85	-0.8	0.67	0.65	0.91		0.61	0.73	-0.69	0.88	0.89	0.79	0.69	0.9	0.81	0.95	0.76	0.92	0.71
Other Assets	0.54	0.74	0.79	-0.9	0.94	-0.86	0.51	0.88	-0.96	0.62	0.61	0.59	0.61		0.49	-0.67	0.87	0.78	0.67	0.73	0.79	0.55	0.51	0.52	0.49	0.45
Cash And Short Term Investments	0.99	0.75	0.84	-0.43	0.58	-0.39	0.85	0.58	-0.66	0.9	0.93	0.84	0.73	0.49		-0.67	0.71	0.68	0.75	0.78	0.69	0.91	0.85	1.0	0.81	1.0
Common Stock Total Equity	-0.71	-0.73	-0.79	0.51	-0.73	0.62	-0.76	-0.73	0.76	-0.46	-0.52	-0.71	-0.69	-0.67	-0.67		-0.79	-0.62	-0.81	-0.87	-0.63	-0.88	-0.76	-0.69	-0.72	-0.63
Common Stock Shares Outstanding	0.78	0.96	0.97	-0.87	0.94	-0.87	0.8	0.94	-0.96	0.73	0.73	0.86	0.88	0.87	0.71	-0.79		0.95	0.8	0.84	0.96	0.81	0.8	0.75	0.77	0.68
Non Current Liabilities Total	0.76	0.95	0.93	-0.9	0.89	-0.89	0.78	0.93	-0.89	0.76	0.72	0.9	0.89	0.78	0.68	-0.62	0.95		0.69	0.67	1.0	0.72	0.78	0.71	0.79	0.65
Other Current Assets	0.79	0.83	0.86	-0.54	0.68	-0.56	0.85	0.67	-0.76	0.69	0.73	0.74	0.79	0.67	0.75	-0.81	0.8	0.69		0.87	0.71	0.82	0.85	0.78	0.8	0.74
Other Stockholder Equity	0.79	0.79	0.89	-0.53	0.71	-0.52	0.73	0.66	-0.81	0.71	0.77	0.66	0.69	0.73	0.78	-0.87	0.84	0.67	0.87		0.69	0.84	0.73	0.8	0.62	0.74
Total Liab	0.77	0.95	0.94	-0.9	0.9	-0.88	0.79	0.93	-0.89	0.77	0.73	0.9	0.9	0.79	0.69	-0.63	0.96	1.0	0.71	0.69		0.74	0.79	0.72	0.8	0.66
Net Invested Capital	0.94	0.82	0.88	-0.49	0.67	-0.54	0.91	0.71	-0.72	0.72	0.76	0.9	0.81	0.55	0.91	-0.88	0.81	0.72	0.82	0.84	0.74		0.91	0.93	0.89	0.9
Property Plant And Equipment Gross	0.89	0.91	0.88	-0.58	0.69	-0.61	1.0	0.75	-0.71	0.7	0.71	0.92	0.95	0.51	0.85	-0.76	0.8	0.78	0.85	0.73	0.79	0.91		0.87	0.97	0.84
Total Current Assets	1.0	0.78	0.86	-0.47	0.61	-0.43	0.87	0.62	-0.69	0.9	0.93	0.86	0.76	0.52	1.0	-0.69	0.75	0.71	0.78	0.8	0.72	0.93	0.87		0.83	0.99
Non Current Liabilities Other	0.87	0.87	0.84	-0.59	0.68	-0.65	0.97	0.76	-0.67	0.67	0.66	0.96	0.92	0.49	0.81	-0.72	0.77	0.79	0.8	0.62	0.8	0.89	0.97	0.83		0.81
Net Working Capital	0.99	0.72	0.81	-0.4	0.54	-0.35	0.84	0.55	-0.62	0.89	0.92	0.83	0.71	0.45	1.0	-0.63	0.68	0.65	0.74	0.74	0.66	0.9	0.84	0.99	0.81

Click cells to compare fundamentals

BridgeBio Pharma Account Relationship Matchups

BridgeBio Pharma fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	631.7M	703.6M	1.0B	623.0M	546.4M	641.2M
Other Current Liab	4.1M	81.5M	118.2M	98.0M	118.8M	70.1M
Total Current Liabilities	52.4M	91.9M	130.1M	117.8M	143.8M	90.7M
Total Stockholder Equity	408.5M	57.9M	(870.4M)	(1.3B)	(1.4B)	(1.3B)
Other Liab	3.5M	7.9M	22.1M	26.6M	30.6M	32.2M
Net Tangible Assets	408.5M	59.5M	(915.3M)	(1.3B)	(1.2B)	(1.1B)
Property Plant And Equipment Net	5.6M	36.8M	46.0M	25.2M	19.8M	21.3M
Net Debt	(264.0M)	139.7M	1.3B	1.3B	1.4B	1.4B
Retained Earnings	(440.0M)	(888.8M)	(1.4B)	(1.9B)	(2.6B)	(2.4B)
Accounts Payable	8.9M	8.9M	11.9M	11.6M	10.7M	10.6M
Cash	363.8M	356.1M	393.8M	376.7M	375.9M	376.3M
Non Current Assets Total	31.9M	60.8M	173.1M	117.8M	68.8M	74.3M
Non Currrent Assets Other	(4.9M)	21.3M	33.0M	20.2M	22.6M	14.8M
Other Assets	26.3M	23.9M	33.0M	140.8M	161.9M	170.0M
Cash And Short Term Investments	577.1M	607.1M	787.5M	428.3M	434.9M	528.5M
Common Stock Total Equity	124K	125K	154K	157K	141.3K	134.2K
Common Stock Shares Outstanding	105.1M	118.0M	144.4M	147.5M	162.8M	135.5M
Liabilities And Stockholders Equity	631.7M	703.6M	1.0B	623.0M	546.4M	641.2M
Non Current Liabilities Total	103.3M	503.8M	1.7B	1.8B	1.7B	1.0B
Other Current Assets	22.6M	71.3M	32.4M	59.9M	41.0M	36.2M
Other Stockholder Equity	845.9M	946.3M	566.5M	663.7M	1.2B	664.4M
Total Liab	155.7M	595.7M	1.9B	1.9B	1.9B	1.1B
Net Invested Capital	500.2M	535.2M	833.4M	453.0M	372.5M	397.1M
Property Plant And Equipment Gross	5.6M	36.8M	46.0M	25.2M	19.8M	21.3M
Total Current Assets	599.8M	642.8M	839.7M	505.2M	477.6M	566.9M
Accumulated Other Comprehensive Income	254K	192K	(132K)	(328K)	31K	32.6K
Non Current Liabilities Other	3.5M	24.2M	39.5M	26.6M	9.4M	16.3M
Net Working Capital	508.2M	547.2M	709.6M	387.4M	333.7M	469.5M
Common Stock	124K	125K	154K	157K	181K	172.0K
Property Plant Equipment	5.6M	20.3M	46.0M	14.6M	16.8M	16.2M
Short Long Term Debt Total	99.8M	495.8M	1.7B	1.7B	1.7B	1.1B
Long Term Debt	91.8M	475.9M	1.7B	1.7B	1.7B	1.1B
Long Term Debt Total	91.8M	475.9M	1.7B	1.7B	2.0B	2.1B
Capital Stock	124K	125K	154K	157K	181K	172.0K

Pair Trading with BridgeBio Pharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if BridgeBio Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BridgeBio Pharma will appreciate offsetting losses from the drop in the long position's value.

Moving together with BridgeBio Stock

0.68

DMAC

DiaMedica Therapeutics

Pair Corr

Moving against BridgeBio Stock

0.6	VIGL	Vigil Neuroscience	Pair Corr
0.52	VALN	Valneva SE ADR	Pair Corr
0.5	DTIL	Precision BioSciences	Pair Corr
0.49	DRRX	Durect	Pair Corr
0.33	EQ	Equillium	Pair Corr

The ability to find closely correlated positions to BridgeBio Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace BridgeBio Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back BridgeBio Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling BridgeBio Pharma to buy it.

The correlation of BridgeBio Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as BridgeBio Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if BridgeBio Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for BridgeBio Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether BridgeBio Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BridgeBio Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bridgebio Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bridgebio Pharma Stock:

How To Invest In BridgeBio

Details

Is BridgeBio Stock a good investment?

Details

What is BridgeBio Pharma's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BridgeBio Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in BridgeBio Stock, please use our How to Invest in BridgeBio Pharma guide.

You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BridgeBio Pharma. If investors know BridgeBio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BridgeBio Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.42)

Revenue Per Share

1.194

Quarterly Revenue Growth

(0.33)

Return On Assets

(0.49)

Return On Equity

(17.90)

The market value of BridgeBio Pharma is measured differently than its book value, which is the value of BridgeBio that is recorded on the company's balance sheet. Investors also form their own opinion of BridgeBio Pharma's value that differs from its market value or its book value, called intrinsic value, which is BridgeBio Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BridgeBio Pharma's market value can be influenced by many factors that don't directly affect BridgeBio Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between BridgeBio Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if BridgeBio Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BridgeBio Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

BridgeBio Short Long Term Debt vs Current Deferred Revenue Analysis

Short Long Term Debt vs Current Deferred Revenue

Short Long Term Debt vs Current Deferred Revenue Correlation Analysis

Correlation Coefficient

Short Long Term Debt

Current Deferred Revenue

BridgeBio Pharma fundamental ratios Correlations

BridgeBio Pharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

BridgeBio Pharma fundamental ratios Accounts

Pair Trading with BridgeBio Pharma

Moving together with BridgeBio Stock

Moving against BridgeBio Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Total Current Assets	+ 1.0	Cash And Short Term Investments
Net Working Capital	+ 1.0	Cash And Short Term Investments
Total Liab	+ 1.0	Non Current Liabilities Total
Cash And Short Term Investments	+ 0.99	Total Assets

Retained Earnings	- 0.98	Other Liab
Net Debt	- 0.97	Net Tangible Assets
Common Stock Shares Outstanding	- 0.96	Retained Earnings
Other Assets	- 0.96	Retained Earnings
Other Liab	- 0.96	Total Stockholder Equity
Net Tangible Assets	- 0.95	Other Liab